HIV Controllers: A Genetically Determined Or Inducible Phenotype?

Immunological Reviews

Volumn 254, Issue 1, 2013, Pages 281-294

  Sáez Cirión, Asier ^a   Pancino, Gianfranco ^a,b  

^a INSTITUT PASTEUR   (France)

^b INSERM   (France)

Author keywords

Antiviral responses; HIV controllers; HIV 1; Post treatment controllers; Viral reservoirs

Indexed keywords

CD38 ANTIGEN; CYTOKINE; HLA B ANTIGEN; HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DS1;

ADAPTIVE IMMUNITY; ALLELE; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL LOSS; CYTOTOXIC T LYMPHOCYTE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION CONTROL; INNATE IMMUNITY; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTOMICS; VIREMIA; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS IMMUNITY; VIRUS LOAD; VIRUS MUTATION; VIRUS PATHOGENESIS; VIRUS REPLICATION;

ADAPTIVE IMMUNITY; ANIMALS; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE;

EID: 84879320681     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12076     Document Type: Article

References (140)

1. Deacon NJ, et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995;270:988-991.
2. Hirsch VM, et al. Vpx is required for dissemination and pathogenesis of SIV(SM) PBj: evidence of macrophage-dependent viral amplification. Nat Med 1998;4:1401-1408.
3. Verhofstede C, Nijhuis M, Vandekerckhove L. Correlation of coreceptor usage and disease progression. Curr Opin HIV AIDS 2012;7:432-439.
4. Brass AL, et al. Identification of host proteins required for HIV infection through a functional genomic screen. Science 2008;319:921-926.
5. Konig R, et al. Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 2008;135:49-60.
6. Yan N, Chen ZJ. Intrinsic antiviral immunity. Nat Immunol 2012;13:214-222.
7. Lambotte O, et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 2005;41:1053-1056.
8. Migueles SA, et al. HLA B5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA 2000;97:2709-2714.
9. Okulicz JF, et al. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis 2009;200:1714-1723.
10. Pereyra F, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 2008;197:563-571.
11. Saez-Cirion A, Pancino G, Sinet M, Venet A, Lambotte O. HIV controllers: how do they tame the virus? Trends Immunol 2007;28:532-540.
12. Madec Y, Boufassa F, Porter K, Meyer L. Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters. AIDS 2005;19:2001-2007.
13. Boufassa F, et al. CD4 dynamics over a 15 year-period among HIV controllers enrolled in the ANRS French observatory. PLoS ONE 2011;6:e18726.
14. Grabar S, Selinger-Leneman H, Abgrall S, Pialoux G, Weiss L, Costagliola D. Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS 2009;23:1163-1169.
15. Saez-Cirion A, Pancino G, Lambotte O. Definition, natural history and heterogeneity of HIV controllers. In: Pancino G, Silvestri G, Fowke KR eds. Models of Protection Against HIV/SIV Avoiding AIDS in Humans and Monkeys. Amsterdam: Academic Press, 2012:233-252.
16. Goujard C, et al. Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established? Clin Infect Dis 2009;49:982-986.
17. Kim AY, et al. Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. Gastroenterology 2011;140:686-696. e681.
18. Ruiz-Mateos E, et al. Hepatitis C virus replication in Caucasian HIV controllers. J Viral Hepat 2011;18:e350-e357.
19. Hatano H, et al. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol 2009;83:329-335.
20. Mens H, et al. HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol 2010;84:12971-12981.
21. Pereyra F, et al. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis 2009;200:984-990.
22. Dahl V, et al. Single-copy assay quantification of HIV-1 RNA in paired cerebrospinal fluid and plasma samples from elite controllers. AIDS 2013;27:1145-1149.
23. Probasco JC, et al. Cerebrospinal fluid in HIV-1 systemic viral controllers: absence of HIV-1 RNA and intrathecal inflammation. AIDS 2010;24:1001-1005.
24. Hunt PW, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008;197:126-133.
25. Vigneault F, et al. Transcriptional profiling of CD4 T cells identifies distinct subgroups of HIV-1 elite controllers. J Virol 2011;85:3015-3019.
26. Okulicz JF, et al. CD4 T cell count reconstitution in HIV controllers after highly active antiretroviral therapy. Clin Infect Dis 2010;50:1187-1191.
27. Sedaghat AR, Rastegar DA, O'Connell KA, Dinoso JB, Wilke CO, Blankson JN. T cell dynamics and the response to HAART in a cohort of HIV-1-infected elite suppressors. Clin Infect Dis 2009;49:1763-1766.
28. Brenchley JM, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12:1365-1371.
29. Potter SJ, et al. Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J Virol 2007;81:13904-13915.
30. Yang Y, et al. CD4 T-cell regeneration in HIV-1 elite controllers. AIDS 2012;26:701-706.
31. Sauce D, et al. HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood 2011;117:5142-5151.
32. Bailey JR, Williams TM, Siliciano RF, Blankson JN. Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med 2006;203:1357-1369.
33. Dinoso JB, Kim SY, Siliciano RF, Blankson JN. A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy. Clin Infect Dis 2008;47:102-104.
34. Blankson JN, et al. Isolation and Characterization of Replication-Competent HIV-1 from a Subset of Elite Suppressors. J Virol 2007;81:2508-2518.
35. Lewin SR, Rouzioux C. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS 2011;25:885-897.
36. O'Connell KA, Brennan TP, Bailey JR, Ray SC, Siliciano RF, Blankson JN. Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol 2010;84:7018-7028.
37. Salgado M, et al. Evolution of the HIV-1 nef gene in HLA-B*57 positive elite suppressors. Retrovirology 2010;7:94.
38. Schneidewind A, et al. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol 2007;81:12382-12393.
39. Brockman MA, et al. Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J Virol 2007;81:12608-12618.
40. Miura T, et al. HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition. J Virol 2009;83:2743-2755.
41. Martinez-Picado J, et al. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol 2006;80:3617-3623.
42. Miura T, et al. HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1. J Virol 2009;83:140-149.
43. Lassen KG, et al. Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS Pathog 2009;5:e1000377.
44. Brumme ZL, et al. Reduced replication capacity of NL4-3 recombinant viruses encoding reverse transcriptase-integrase sequences from HIV-1 elite controllers. J Acquir Immune Defic Syndr 2011;56:100-108.
45. Mwimanzi P, et al. Attenuation of multiple Nef functions in HIV-1 elite controllers. Retrovirology 2012;10:1.
46. Miura T, et al. Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. J Virol 2008;82:8422-8430.
47. Miura T, et al. Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol 2010;84:7581-7591.
48. Lamine A, et al. Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study). AIDS 2007;21:1043-1045.
49. Saez-Cirion A, et al. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol 2009;182:7828-7837.
50. Julg B, et al. Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers. Clin Infect Dis 2010;51:233-238.
51. Buckheit RW 3rd, et al. Host factors dictate control of viral replication in two HIV-1 controller/chronic progressor transmission pairs. Nat Comm 2012;3:716.
52. Navis M, et al. Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection. J Immunol 2007;179:3133-3143.
53. Bailey JR, et al. Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. J Virol 2008;82:7395-7410.
54. Fellay J, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007;317:944-947.
55. Limou S, et al. Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02). J Infect Dis 2009;199:419-426.
56. Kaslow RA, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996;2:405-411.
57. Pelak K, et al. Host determinants of HIV-1 control in African Americans. J Infect Dis 2010;201:1141-1149.
58. McLaren PJ, et al. Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans. Hum Mol Genet 2012;21:4334-4347.
59. Pereyra F, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010;330:1551-1557.
60. Thomas R, et al. HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet 2009;41:1290-1294.
61. Kulkarni S, et al. Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature 2011;472:495-498.
62. Goldstein DB. Common genetic variation and human traits. N Engl J Med 2009;360:1696-1698.
63. Martin MP, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002;31:429-434.
64. Kamya P, et al. Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57. J Virol 2011;85:5949-5960.
65. Martin MP, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007;39:733-740.
66. Tomescu C, et al. Impact of protective killer inhibitory receptor/human leukocyte antigen genotypes on natural killer cell and T-cell function in HIV-1-infected controllers. AIDS 2012;26:1869-1878.
67. O'Connell KA, Han Y, Williams TM, Siliciano RF, Blankson JN. Role of natural killer cells in a cohort of elite suppressors: low frequency of the protective KIR3DS1 allele and limited inhibition of human immunodeficiency virus type 1 replication in vitro. J Virol 2009;83:5028-5034.
68. Sáez-Cirión A, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar CTL activation phenotype. Proc Natl Acad Sci USA 2007;104:6776-6781.
69. Day CL, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006;443:350-354.
70. Petrovas C, et al. Differential association of programmed death-1 and CD57 with ex vivo survival of CD8+ T cells in HIV infection. J Immunol 2009;183:1120-1132.
71. Giorgi JV, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999;179:859-870.
72. Horton H, et al. Preservation of T cell proliferation restricted by protective HLA alleles is critical for immune control of HIV-1 infection. J Immunol 2006;177:7406-7415.
73. Betts MR, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006;107:4781-4789.
74. Streeck H, et al. Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med 2008;5:e100.
75. Migueles SA, et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002;3:1061-1068.
76. Migueles SA, et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 2008;29:1009-1021.
77. Hersperger AR, et al. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog 2010;6:e1000917.
78. Addo MM, et al. Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection. PLoS ONE 2007;2:e321.
79. Chen H, et al. Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes. J Virol 2009;83:3138-3149.
80. Kiepiela P, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007;13:46-53.
81. Pontesilli O, et al. Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection. J Infect Dis 1998;178:1008-1018.
82. Edwards BH, Bansal A, Sabbaj S, Bakari J, Mulligan MJ, Goepfert PA. Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol 2002;76:2298-2305.
83. Descours B, et al. Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells. Clin Infect Dis 2012;54:1495-1503.
84. Ferre AL, et al. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 2009;113:3978-3989.
85. Ferre AL, et al. Immunodominant HIV-specific CD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of HIV controllers. J Virol 2010;84:10354-10365.
86. Miura T, et al. HLA-associated viral mutations are common in human immunodeficiency virus type 1 elite controllers. J Virol 2009;83:3407-3412.
87. Wang YE, et al. Protective HLA class I alleles that restrict acute-phase CD8+ T-cell responses are associated with viral escape mutations located in highly conserved regions of human immunodeficiency virus type 1. J Virol 2009;83:1845-1855.
88. Berger CT, et al. High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control. J Virol 2011;85:9334-9345.
89. Mothe B, et al. CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PLoS ONE 2012;7:e29717.
90. Almeida JR, et al. Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood 2009;113:6351-6360.
91. Chen H, et al. TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat Immunol 2012;13:691-700.
92. Ladell K, et al. A molecular basis for the control of pre-immune escape variants by HIV-specific CD8+ T-cells. Immunity 2013;38:425-436.
93. Huang J, et al. Leukocyte immunoglobulin-like receptors maintain unique antigen-presenting properties of circulating myeloid dendritic cells in HIV-1-infected elite controllers. J Virol 2010;84:9463-9471.
94. Lecuroux C, et al. CD8 T-cells from most HIV-infected patients lack HIV-suppressive capacity during acute and early infection. PLoS ONE 2013;8:e59767.
95. Emu B, et al. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J Virol 2008;82:5398-5407.
96. Buckheit RW 3rd, Salgado M, Silciano RF, Blankson JN. Inhibitory Potential of Subpopulations of CD8+ T Cells in HIV-1 Infected Elite Suppressors. J Virol 2012;86:13679-13688.
97. Ndhlovu ZM, et al. Elite controllers with low to absent effector CD8+ T cell responses maintain highly functional, broadly directed central memory responses. J Virol 2012;86:6959-6969.
98. Shan L, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012;36:491-501.
99. Schulze Zur Wiesch J, et al. Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease. J Virol 2011;85:1287-1297.
100. Angin M, et al. Preserved function of regulatory T cells in chronic HIV-1 infection despite decreased numbers in blood and tissue. J Infect Dis 2012;205:1495-1500.
101. Shaw JM, et al. Increased frequency of regulatory T cells accompanies increased immune activation in rectal mucosae of HIV-positive noncontrollers. J Virol 2011;85:11422-11434.
102. Hunt PW, et al. A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS ONE 2011;6:e15924.
103. Lambotte O, et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009;23:897-906.
104. Deepe RN, Kistner-Griffin E, Martin JN, Deeks SG, Pandey JP. Epistatic interactions between Fc (GM) and FcgammaR genes and the host control of human immunodeficiency virus replication. Hum Immunol 2012;73:263-266.
105. Liu Q, et al. Matrix metalloprotease inhibitors restore impaired NK cell-mediated antibody-dependent cellular cytotoxicity in human immunodeficiency virus type 1 infection. J Virol 2009;83:8705-8712.
106. Mendoza D, et al. Comprehensive analysis of unique cases with extraordinary control over HIV replication. Blood 2012;119:4645-4655.
107. Rotger M, et al. Genome-wide mRNA expression correlates of viral control in CD4+ T-cells from HIV-1-infected individuals. PLoS Pathog 2010;6:e1000781.
108. Owen RE, et al. HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses. AIDS 2010;24:1095-1105.
109. Vingert B, et al. HIV controllers maintain a population of highly efficient Th1 effector cells in contrast to patients treated in the long term. J Virol 2012;86:10661-10674.
110. Kaufmann DE, et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol 2007;8:1246-1254.
111. Emu B, et al. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol 2005;79:14169-14178.
112. van Grevenynghe J, et al. Transcription factor FOXO3a controls the persistence of memory CD4(+) T cells during HIV infection. Nat Med 2008;14:266-274.
113. Vingert B, et al. HIV controller CD4+ T cells respond to minimal amounts of Gag antigen due to high TCR avidity. PLoS Pathog 2010;6:e1000780.
114. Ferre AL, et al. HIV controllers with HLA-DRB1*13 and HLA-DQB1*06 alleles have strong, polyfunctional mucosal CD4+ T-cell responses. J Virol 2010;84:11020-11029.
115. Chomont N, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009;15:893-900.
116. Chen H, et al. CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest 2011;121:1549-1560.
117. Saez-Cirion A, et al. Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. Blood 2011;118:955-964.
118. Buzon MJ, et al. Inhibition of HIV-1 integration in ex vivo-infected CD4 T cells from elite controllers. J Virol 2011;85:9646-9650.
119. Zhang J, Scadden DT, Crumpacker CS. Primitive hematopoietic cells resist HIV-1 infection via p21. J Clin Invest 2007;117:473-481.
120. Bergamaschi A, David A, Le Rouzic E, Nisole S, Barre-Sinoussi F, Pancino G. The CDK inhibitor p21Cip1/WAF1 is induced by FcgammaR activation and restricts the replication of human immunodeficiency virus type 1 and related primate lentiviruses in human macrophages. J Virol 2009;83:12253-12265.
121. O'Connell KA, Rabi SA, Siliciano RF, Blankson JN. CD4+ T cells from elite suppressors are more susceptible to HIV-1 but produce fewer virions than cells from chronic progressors. Proc Natl Acad Sci USA 2011;108:E689-E698.
122. Palacios JA, et al. Long-term nonprogressor and elite controller patients who control viremia have a higher percentage of methylation in their HIV-1 proviral promoters than aviremic patients receiving highly active antiretroviral therapy. J Virol 2012;86:13081-13084.
123. Deeks SG, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012;12:607-614.
124. Goujard C, et al. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. Antivir Ther 2012;17:1001-1009.
125. Hocqueloux L, et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 2010;24:1598-1601.
126. Lodi S, et al. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med 2012;172:1252-1255.
127. Saez-Cirion A, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy. ANRS VISCONTI study. PLoS Pathog 2013;9:e1003211.
128. Van Gulck E, et al. Immune and viral correlates of "secondary viral control" after treatment interruption in chronically HIV-1 infected patients. PLoS ONE 2012;7:e37792.
129. Ngo-Giang-Huong N, et al. Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy. AIDS 2001;15:665-673.
130. Delwart E, et al. Homogeneous quasispecies in 16 out of 17 individuals during very early HIV-1 primary infection. AIDS 2002;16:189-195.
131. Alter G, et al. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood 2005;106:3366-3369.
132. Moir S, et al. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood 2010;116:5571-5579.
133. Oxenius A, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci USA 2000;97:3382-3387.
134. Petrovas C, et al. CD4 T follicular helper cell dynamics during SIV infection. J Clin Invest 2012;122:3281-3294.
135. Lindqvist M, et al. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J Clin Invest 2012;122:3271-3280.
136. Hong JJ, Amancha PK, Rogers K, Ansari AA, Villinger F. Spatial alterations between CD4(+) T follicular helper, B, and CD8(+) T cells during simian immunodeficiency virus infection: T/B cell homeostasis, activation, and potential mechanism for viral escape. J Immunol 2012;188:3247-3256.
137. Perreau M, et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med 2012;210:143-156.
138. Pancino G, Silvestri G, Fowke K. Models of Protection Against HIV/SIV. Avoiding AIDS in Humans and Monkeys. Amsterdam: Academic Press, 2012.
139. Mudd PA, et al. Vaccine-induced CD8+ T cells control AIDS virus replication. Nature 2012;491:129-133.
140. Hansen SG, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011;473:523-527.